metoprolol has been researched along with Kidney Diseases in 18 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to compare cardiovascular and renal events in patients with hypertension receiving the angiotensin II-receptor blocker valsartan versus those receiving the angiotensin-converting-enzyme lisinopril or the beta-blocker metoprolol succinate in an extended-release formulation." | 7.74 | Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. ( Delea, TE; Frech-Tamas, F; Moynahan, A; Oster, G; Taneja, C; Thomas, SK, 2007) |
| " We therefore investigated the influence of CYP2D6 polymorphism on steady-state plasma concentrations and apparent oral clearance of metoprolol in patients with cardiovascular diseases." | 5.12 | The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. ( Ismail, R; Teh, LK, 2006) |
| "The African American Study of Kidney Disease and Hypertension was a multicenter trial comparing the effects of 2 levels of blood pressure control (usual or low goal) and initial therapy with metoprolol, ramipril, or amlodipine." | 5.12 | Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. ( Gadegbeku, CA; Greene, T; Hall, Y; Jones, K; Kusek, JW; Lash, JP; Sika, M; Unruh, M; Wang, X, 2006) |
| "The objective of this study was to compare cardiovascular and renal events in patients with hypertension receiving the angiotensin II-receptor blocker valsartan versus those receiving the angiotensin-converting-enzyme lisinopril or the beta-blocker metoprolol succinate in an extended-release formulation." | 3.74 | Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. ( Delea, TE; Frech-Tamas, F; Moynahan, A; Oster, G; Taneja, C; Thomas, SK, 2007) |
| " The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS)." | 1.28 | Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ( Aberg, J; Gelin, A; Karlberg, BE; Larsson, R; Regårdh, CG, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Akgüllü, Ç | 1 |
| Eryılmaz, U | 1 |
| Güngör, H | 1 |
| Huyut, A | 1 |
| Zencir, C | 1 |
| Hekim, T | 1 |
| Ito, H | 1 |
| Nagatomo, Y | 1 |
| Kohno, T | 1 |
| Anzai, T | 1 |
| Meguro, T | 1 |
| Ogawa, S | 1 |
| Yoshikawa, T | 1 |
| Davis, EM | 1 |
| Appel, LJ | 1 |
| Wang, X | 2 |
| Greene, T | 2 |
| Astor, BC | 1 |
| Rahman, M | 1 |
| Toto, R | 1 |
| Lipkowitz, MS | 1 |
| Pogue, VA | 1 |
| Wright, JT | 1 |
| Chobanian, AV | 1 |
| El-Gowilly, SM | 1 |
| Avci, E | 1 |
| Yeşil, M | 1 |
| Bayata, S | 1 |
| Postaci, N | 1 |
| Arikan, E | 1 |
| Cirit, M | 1 |
| Dorne, JL | 1 |
| Walton, K | 1 |
| Slob, W | 1 |
| Renwick, AG | 1 |
| Ismail, R | 1 |
| Teh, LK | 1 |
| Lash, JP | 1 |
| Gadegbeku, CA | 1 |
| Hall, Y | 1 |
| Jones, K | 1 |
| Kusek, JW | 1 |
| Sika, M | 1 |
| Unruh, M | 1 |
| Fomin, VV | 1 |
| Safonov, VV | 1 |
| Kozlovskaia, NL | 1 |
| Moiseev, SV | 1 |
| Osipenko, VI | 1 |
| Tironishvili, OI | 1 |
| Almquist, T | 1 |
| Forslund, L | 1 |
| Rehnqvist, N | 1 |
| Hjemdahl, P | 1 |
| Delea, TE | 1 |
| Taneja, C | 1 |
| Moynahan, A | 1 |
| Thomas, SK | 1 |
| Frech-Tamas, F | 1 |
| Oster, G | 1 |
| Coevoet, B | 1 |
| Lambrey, G | 1 |
| de Frémont, JF | 1 |
| Hardin, JM | 1 |
| Desplan, C | 1 |
| Calmette, C | 1 |
| Makdassi, R | 1 |
| Andrejak, M | 1 |
| Moukhtar, MS | 1 |
| Fournier, A | 1 |
| Kuhn, U | 1 |
| Kuhn, W | 1 |
| Grospietsch, G | 1 |
| Engelmann, A | 1 |
| Girndt, J | 1 |
| Larsson, R | 1 |
| Karlberg, BE | 1 |
| Gelin, A | 1 |
| Aberg, J | 1 |
| Regårdh, CG | 1 |
| Lloyd, P | 1 |
| John, VA | 1 |
| Signy, M | 1 |
| Smith, SE | 1 |
| Rambausek, M | 1 |
| Ritz, E | 1 |
| Mall, G | 1 |
| Mehls, O | 1 |
| Katus, H | 1 |
5 trials available for metoprolol and Kidney Diseases
| Article | Year |
|---|---|
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Female; | 2011 |
The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Benzopyrans; Contrast Media; Coronary Angiography; Coronary Artery D | 2011 |
The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Cardiovascular Dise | 2006 |
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Press | 2006 |
Prognostic implications of renal dysfunction in patients with stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Disease | 2006 |
13 other studies available for metoprolol and Kidney Diseases
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
A clinical study about contrast nephropathy: risk factors and the role of beta blockers.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contrast Media; Cross-Sectional Studies; Female | 2015 |
Differential effects of carvedilol and metoprolol on renal function in patients with heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; Carvedilol; Drug Evaluation; Female; Glome | 2010 |
Mixed messages on blood pressure goals.
Topics: Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Glomerular Filtratio | 2011 |
Metoprolol ameliorates cyclosporine a-induced hypertension and nephrotoxicity in rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antioxidants; Blood Pressure; Carbachol; Cyclospori | 2011 |
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoqu | 2002 |
[Ischemic disease of the kidneys in a patient with morbid obesity: characteristics of the course and diagnostic policy].
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Diagnosis, Differential; Health Policy; Human | 2006 |
Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Delayed-Action Preparations; Female; Humans; Hyper | 2007 |
[Evidence, in uremic man, of the role of beta 2 adrenergic receptors in the secretion of parathyroid hormone and calcitonin (author's transl)].
Topics: Adult; Calcitonin; Female; Heart Rate; Humans; Kidney Diseases; Male; Metoprolol; Parathyroid Hormon | 1980 |
[The effect of metoprolol on fenoterol-induced kidney function disorders].
Topics: Animals; Creatinine; Electrolytes; Ethanolamines; Female; Fenoterol; Hematocrit; Hemoglobins; Kidney | 1983 |
Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.
Topics: Adult; Aged; Biological Availability; Blood Pressure; Felodipine; Female; Furosemide; Glomerular Fil | 1990 |
The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system.
Topics: Administration, Oral; Delayed-Action Preparations; Humans; Kidney Diseases; Male; Metoprolol; Osmola | 1990 |
Myocardial hypertrophy in rats with renal insufficiency.
Topics: Adenosine Triphosphatases; Animals; Blood Pressure; Blood Transfusion; Calcium; Cardiomegaly; Hydral | 1985 |